JP5603770B2 - Ｃｃｒ２受容体拮抗薬およびその使用 - Google Patents

Ｃｃｒ２受容体拮抗薬およびその使用 Download PDF

Info

Publication number
JP5603770B2
JP5603770B2 JP2010509818A JP2010509818A JP5603770B2 JP 5603770 B2 JP5603770 B2 JP 5603770B2 JP 2010509818 A JP2010509818 A JP 2010509818A JP 2010509818 A JP2010509818 A JP 2010509818A JP 5603770 B2 JP5603770 B2 JP 5603770B2
Authority
JP
Japan
Prior art keywords
phenyl
amino
chloro
methyl
quinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010509818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528089A5 (enExample
JP2010528089A (ja
Inventor
ハイナー エーベル
シュテファン ペーターズ
ジルケ ホビー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2010528089A publication Critical patent/JP2010528089A/ja
Publication of JP2010528089A5 publication Critical patent/JP2010528089A5/ja
Application granted granted Critical
Publication of JP5603770B2 publication Critical patent/JP5603770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010509818A 2007-05-31 2008-05-29 Ｃｃｒ２受容体拮抗薬およびその使用 Active JP5603770B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109376.9 2007-05-31
EP07109376 2007-05-31
PCT/EP2008/056573 WO2008145681A2 (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof

Publications (3)

Publication Number Publication Date
JP2010528089A JP2010528089A (ja) 2010-08-19
JP2010528089A5 JP2010528089A5 (enExample) 2011-07-14
JP5603770B2 true JP5603770B2 (ja) 2014-10-08

Family

ID=38752546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010509818A Active JP5603770B2 (ja) 2007-05-31 2008-05-29 Ｃｃｒ２受容体拮抗薬およびその使用

Country Status (8)

Country Link
US (1) US8653262B2 (enExample)
EP (1) EP2155689B1 (enExample)
JP (1) JP5603770B2 (enExample)
AR (1) AR066799A1 (enExample)
CA (1) CA2687931C (enExample)
CL (1) CL2008001593A1 (enExample)
TW (1) TW200904434A (enExample)
WO (1) WO2008145681A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55634B1 (sr) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
HUE043732T2 (hu) 2007-06-13 2019-09-30 Incyte Holdings Corp Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
JP5250627B2 (ja) 2007-08-14 2013-07-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
US20100331298A1 (en) * 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
US20110301350A1 (en) * 2008-08-12 2011-12-08 Boehringer Ingelheim International Gmbh Process for preparing cycloalkyl-substituted piperazine compounds
AU2009308687A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
MX2011005150A (es) 2008-12-19 2011-05-30 Boehringer Ingelheim Int Pirimidin-4-carboxamidas ciclicas como antagonistas del receptor ccr2 para el tratamiento de inflamacion, asma y epoc.
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK2513093T3 (da) 2009-12-17 2014-09-29 Boehringer Ingelheim Int Nye CCR2 receptor antagonister og anvendelser deraf
TWI531572B (zh) 2010-03-10 2016-05-01 英塞特公司 作為ｊａｋ１抑制劑之哌啶－４－基三亞甲亞胺衍生物
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
JP5636094B2 (ja) * 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2012253237B2 (en) * 2011-05-12 2015-09-24 Bionomics Limited Methods for preparing naphthyridines
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US20140329809A1 (en) 2011-10-28 2014-11-06 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CR20190073A (es) 2012-11-15 2019-04-25 Incyte Holdings Corp FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
SMT202100694T1 (it) 2013-03-06 2022-03-21 Incyte Holdings Corp Procedimenti e intermedi per produrre un inibitore di jak
WO2014169087A2 (en) * 2013-04-10 2014-10-16 The Trustees Of Columbia University In The City Of New York Treatment of proximal spinal muscular atrophy
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
CA2920108C (en) 2013-08-07 2022-07-05 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016128343A1 (en) * 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP3317270B1 (en) 2015-07-02 2020-05-13 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
CN112480079B (zh) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4426382A (en) 1980-02-13 1984-01-17 Sankyo Company Limited 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
DE3517617A1 (de) * 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
ES8802151A1 (es) * 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
ES2133416T3 (es) * 1992-10-23 1999-09-16 Merck Sharp & Dohme Ligandos de subtipos de receptores de dopamina.
JP3166376B2 (ja) 1993-02-03 2001-05-14 松下電器産業株式会社 熱利用装置
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JPH1190106A (ja) * 1997-09-26 1999-04-06 Daicel Chem Ind Ltd 擬似移動床式クロマト分離装置
TR200001171T2 (tr) * 1997-10-27 2000-10-23 Neurosearch A/S Nikotinik asetilkolin reseptörlerinde kolinerjik ligandlar olarak heteroaril diazasikloalkalinler
WO2000031072A1 (en) * 1998-11-20 2000-06-02 G.D. Searle & Co. Process for making 5-substituted pyrazoles using dithietanes
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
EP1046593A1 (en) * 1999-04-12 2000-10-25 Heineken Technical Services B.V. Closure for container
TR200103214T2 (tr) 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
AU2001257413B2 (en) 2000-05-22 2007-01-18 Aventisub Llc Arylmethylamine derivatives for use as tryptase inhibitors
US20050143372A1 (en) 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
PL372390A1 (en) * 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
MXPA04007775A (es) * 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
BR0311619A (pt) 2002-06-05 2005-03-08 Pharmacia Corp Derivados de pirazol como inibidores de cinase p38
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004080976A1 (en) 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0409611A (pt) * 2003-04-23 2006-04-18 Glaxo Group Ltd derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
DE602004008291T2 (de) 2003-07-18 2008-05-08 Glaxo Group Limited, Greenford Substituierte piperidine als histamin-h3-rezeptorliganden
DE602004026068D1 (de) 2003-07-29 2010-04-29 High Point Pharmaceuticals Llc Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden
CN1893945A (zh) * 2003-12-18 2007-01-10 因赛特公司 作为趋化因子受体调控剂的3－环烷基氨基吡咯烷衍生物
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CN1972914A (zh) * 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
EP1753740A2 (en) 2004-05-21 2007-02-21 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
US7507740B2 (en) 2004-06-02 2009-03-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2006012135A1 (en) 2004-06-24 2006-02-02 Janssen Pharmaceutica, N. V. Quaternary salt ccr2 antagonists
BRPI0512535A (pt) * 2004-06-24 2008-03-25 Incyte Corp compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
EP1763347A4 (en) 2004-06-28 2009-05-20 Incyte Corp 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
NZ553979A (en) 2004-08-26 2009-05-31 Kudos Pharm Ltd 4-heteroarylmethyl substituted phthalazinone derivatives
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
US8367672B2 (en) * 2004-11-02 2013-02-05 Universite De Strasbourg Pyridazine compounds, compositions and methods
UY29219A1 (es) 2004-11-22 2006-04-28 Incyte Corp Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
DE102004061751A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
AU2005317928B2 (en) * 2004-12-24 2010-06-10 Astrazeneca Ab Heterocyclic compounds as CCR2b antagonists
AU2006214453A1 (en) * 2005-02-16 2006-08-24 Merck Sharp & Dohme Corp. Substituted pyrazoles as modulators of chemokine receptors
RU2408580C2 (ru) * 2005-02-17 2011-01-10 Астеллас Фарма Инк. Пиридильное неароматическое азотсодержащее гетероцикло-1-карбоксилатное производное
JP2008537953A (ja) * 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
EP1902028A2 (en) 2005-07-04 2008-03-26 Novo Nordisk A/S Histamine h3 receptor antagonists
AU2006275568A1 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
CA2622494A1 (en) 2005-09-27 2007-04-05 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US20100016289A1 (en) 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
BRPI0618573A2 (pt) 2005-11-14 2011-09-06 Irm Llc compostos e composições como moduladores de lxr
WO2007084868A2 (en) 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
NZ570847A (en) 2006-02-28 2011-10-28 Helicon Therapeutics Inc Therapeutic compounds
EP2024353A2 (en) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
EP2013174B1 (en) 2006-04-11 2013-05-08 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
EP2015751A2 (en) 2006-04-28 2009-01-21 Northwestern University Salts of pyridazine compounds
WO2007147874A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
WO2008083027A1 (en) * 2006-12-28 2008-07-10 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
US20100204230A1 (en) * 2007-02-12 2010-08-12 Peter Blurton Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
MX2010002005A (es) 2007-08-22 2010-03-11 Irm Llc Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
CA2700691A1 (en) 2007-10-01 2009-04-09 F. Hoffmann-La Roche Ag New biaryl derivatives
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
AU2009259496A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
EP2331095B1 (en) 2008-08-04 2014-10-15 CHDI Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US8735579B2 (en) * 2008-09-02 2014-05-27 Boehringer Ingelheim International Gmbh Benzamides, production thereof, and use thereof as medicaments
MX2011005150A (es) 2008-12-19 2011-05-30 Boehringer Ingelheim Int Pirimidin-4-carboxamidas ciclicas como antagonistas del receptor ccr2 para el tratamiento de inflamacion, asma y epoc.
US20110301143A1 (en) * 2009-02-23 2011-12-08 Elise Isabel Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
DK2513093T3 (da) * 2009-12-17 2014-09-29 Boehringer Ingelheim Int Nye CCR2 receptor antagonister og anvendelser deraf
EP2513086B1 (en) 2009-12-17 2015-04-29 Boehringer Ingelheim International GmbH Novel antagonists for ccr2 and uses thereof
US8946218B2 (en) * 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en) * 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
JP5786257B2 (ja) 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の選択的ｃｃｒ２拮抗薬
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists

Also Published As

Publication number Publication date
CA2687931A1 (en) 2008-12-04
AR066799A1 (es) 2009-09-16
WO2008145681A2 (en) 2008-12-04
EP2155689B1 (en) 2015-07-08
CA2687931C (en) 2016-05-24
WO2008145681A3 (en) 2009-03-05
US20100204209A1 (en) 2010-08-12
US8653262B2 (en) 2014-02-18
TW200904434A (en) 2009-02-01
CL2008001593A1 (es) 2009-09-11
EP2155689A2 (en) 2010-02-24
JP2010528089A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
JP5603770B2 (ja) Ｃｃｒ２受容体拮抗薬およびその使用
EP2816040B1 (en) Process for the production of CCR2 receptor antagonists and intermediates thereof
JP5021624B2 (ja) 炎症性疾患の治療用新規化合物
JP5563466B2 (ja) 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
JP5632014B2 (ja) 新規ｃｃｒ２受容体アンタゴニスト及びこれらの使用
JP5658272B2 (ja) Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
JP5786258B2 (ja) 新規かつ選択的なｃｃｒ２拮抗薬
JP5646736B2 (ja) 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
JP5721242B2 (ja) 新規ｃｃｒ２アンタゴニスト
JP2011500621A (ja) 新規フェニル置換ピペラジノ−ジヒドロチエノピリミジン
US8173699B2 (en) Compounds for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140822

R150 Certificate of patent or registration of utility model

Ref document number: 5603770

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250